Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | BI 891065 |
Synonyms | |
Therapy Description |
BI 891065 is a SMAC mimetic, which antagonizes Inhibitor of apoptosis protein (IAP) family proteins, potentially resulting in increased tumor cell apoptosis and decreased tumor growth (PMID: 29807457). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BI 891065 | BI891065|BI-891065 | SMAC Mimetic 8 | BI 891065 is a SMAC mimetic, which antagonizes Inhibitor of apoptosis protein (IAP) family proteins, potentially resulting in increased tumor cell apoptosis and decreased tumor growth (PMID: 29807457). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03166631 | Phase I | BI 891065 + Ezabenlimab BI 891065 | A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread | Terminated | USA | 0 |